# Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

> **NCT05476939** · PHASE3 · RECRUITING · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 433 (estimated)

## Conditions studied

- Diffuse Intrinsic Pontine Glioma
- Diffuse Midline Glioma, H3 K27M-Mutant
- Diffuse Midline Glioma, H3K27-altered

## Interventions

- **DRUG:** Everolimus
- **DRUG:** ONC201
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT05476939
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-29
- **Primary completion:** 2028-09
- **Final completion:** 2031-09
- **Target enrollment:** 433 (ESTIMATED)
- **Last updated:** 2026-02-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05476939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05476939, "Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT05476939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*